Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04298983 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04298983 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 9 participants.
The verdict
NCT04298983, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This Phase II study is designed to study the clinical and radiologic response, as well as, safety and tolerability of abemaciclib in combination with androgen deprivation therapy (ADT) in patients with localized high-risk or locally advanced prostate cancer who are eligible for definitive radiation therapy (RT) and androgen deprivation therapy (ADT).
Interventions
- RADIATION Radiation Therapy
- DRUG Androgen deprivation therapy (ADT)
- DRUG Abemaciclib 150 MG by mouth twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2024-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04298983
The ClinicalTrials.gov registry entry for NCT04298983 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT04298983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04298983 about?
NCT04298983 is a clinical study titled "Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer". This Phase II study is designed to study the clinical and radiologic response, as well as, safety and tolerability of abemaciclib in combination with androgen deprivation therapy (ADT) in patients with localized high-risk or locally advanced prostate cancer who are eligible for definitive radiation ...
What is the current status of trial NCT04298983?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2021-02-25. Estimated completion is 2024-09-04.
What interventions are being tested in trial NCT04298983?
The interventions under investigation include: Radiation Therapy (RADIATION), Androgen deprivation therapy (ADT) (DRUG), Abemaciclib 150 MG by mouth twice daily (DRUG).
Who is sponsoring clinical trial NCT04298983?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.